Pfizer Inc. (PFE) on Friday reported seven-year follow-up results from the Phase 3 CROWN trial showing that LORBRENA significantly improved progression-free survival compared with XALKORI in patients with previously untreated ALK-positive advanced or metastatic non-small cell lung cancer.
At seven years, 55% of patients treated with LORBRENA remained alive without disease progression, compared with 3% of patients treated with XALKORI. The treatment reduced the risk of disease progression or death by 81% versus XALKORI.
Pfizer said no new safety signals were observed, and the safety profile of both treatments remained consistent with earlier findings.
The company said the results will be presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in Annals of Oncology.
LORBRENA is approved in the U.S. for the treatment of adults with ALK-positive metastatic non-small cell lung cancer. The drug has also been approved in more than 80 countries, including Australia, Canada, China, Japan, South Korea and countries in the European Union.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.